Lu Alleruzzo

Founder at Immunophotonics, Inc.

Health Technology

Consumer Services

Profile

Lu Alleruzzo is the founder of Immunophotonics, Inc., where he currently holds the title of Chief Executive Officer & Director.
Immunophotonics, Inc. was founded in 2009.
Mr. Alleruzzo also has an education background, having obtained an undergraduate degree and an MBA from the University of Missouri.

Lu Alleruzzo active positions

Companies	Position	Start
Immunophotonics, Inc. Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.	Founder	2008-12-31

All active positions of Lu Alleruzzo

Training of Lu Alleruzzo

University of Missouri

Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Lu Alleruzzo's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Immunophotonics, Inc. Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.	Health Technology